Latest Breaking News On - Kairos pharma - Page 1 : vimarsana.com

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Kairos Pharma plans to sell about 1.55 million shares in its initial public offering at $4 per share. The Los Angeles-based company said in a regulatory…

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Kairos Pharma plans to sell about 1.55 million shares in its initial public offering at $4 per share.

Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105 with Apalutamide to Improve Therapy Sensitivity for Castrate-Resistant Prostate Cancer

Kairos Pharma Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105 with Osimertinib to Improve Therapy Sensitivity for EGFR-Driven Lung Cancer

How biotech IPOs performed in the third quarter

BioPharma

IPO Roundup: Abivax, Lexeo Therapeutics and more (Pending:GVH)

Kairos Pharma (KAPA) Announces Proposed IPO

Kairos Pharma Files for IPO

By Stephen Nakrosis Biopharmaceutical company Kairos Pharma filed for an initial public offering with the Securities and Exchange Commission. The company...

Kairos Pharma Receives FDA Approval of Investigational New Drug (IND) Application for Its Phase 1 Clinical Trial of KROS 201 for the Treatment of Glioblastoma; Announces New Patent for KROS 401

/PRNewswire/ -- Kairos Pharma, Ltd. ("Kairos"), a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer,...

Kairos Pharma Announces FDA Clearance of Investigational New Drug (IND) for ENV105 for the Treatment of Prostate Cancer

/PRNewswire/ -- Kairos Pharma, Ltd. ("Kairos"), a privately held clinical stage biotechnology company focused on drug resistance and immunotherapy for cancer,...